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Abstract – During 2007, large outbreaks of equine inﬂuenza (EI) caused by Florida sublineage Clade 1
virusesaffectedhorsepopulationsinJapanandAustralia.Thelikelyprotectionthatwouldbeprovidedbytwo
modern vaccines commercially available in the European Union (an ISCOM-based and a canarypox-based
vaccine)atthetimeoftheoutbreakswasdetermined.Vaccinatedponieswerechallengedwitharepresentative
outbreakisolate(A/eq/Sydney/2888-8/07)andlevelsofprotectionwerecompared.Agroupofponiesinfected
18 months previously with a phylogenetically-related isolate from 2003 (A/eq/South Africa/4/03) was also
challenged with the 2007 outbreak virus. After experimental infection with A/eq/Sydney/2888-8/07,
unvaccinated control ponies all showed clinical signs of infection together with virus shedding. Protection
achieved by both vaccination or long-term immunity induced by previous exposure to equine inﬂuenza virus
(EIV) was characterised by minor signs of disease and reduced virus shedding when compared with
unvaccinated control ponies. The three different methods of virus titration in embryonated hens’ eggs, EIV
NP-ELISA and quantitative RT-PCR were used to monitor EIV shedding and results were compared. Though
the majority of previously infected ponies had low antibody levels at the time of challenge, they demonstrated
goodclinicalprotectionandlimitedvirusshedding.Insummary,wedemonstratethatvaccinationwithcurrent
EIV vaccines would partially protect against infection with A/eq/Sydney/2888-8/07-like strains and would
help to limit the spread of disease in our vaccinated horse population.
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1. INTRODUCTION
Equine inﬂuenza viruses (EIV) are major
respiratory pathogens of horses, causing high
morbidity and occasional mortality. Equine
inﬂuenza (EI) is a highly contagious disease
and is contracted by inhalation of infectious
virus aerosols. EI is not only an important wel-
fare issue but can have a profound economic
impact on the equine industry with major epi-
demics disrupting horse racing and breeding.
In horses, two different subtypes have been
isolated, H7N7 and H3N8. The H7N7 subtype
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Article published by EDP Scienceswas ﬁrst recognised in Eastern Europe in 1956,
in an outbreak where the prototype strain A/eq/
Prague/56 was isolated [31]. The H7N7 viruses
have not been isolated from horses for over 25
years [33].
Equine inﬂuenza H3N8 viruses were ﬁrst
isolated in North America in 1963 [32]a n d
continue to be isolated to this day [2, 17].
Phylogeneticanalysesoftheseisolatesidentiﬁed
a divergence in the evolution of the H3N8
subtype in the late 1980s giving rise to the
Eurasian and American lineages, which have
continued to co-circulate [2, 5]. The American
lineage has subsequently diverged again into
the Kentucky and Florida sublineages [16], the
latter of which has since divided into two sepa-
rate clades, designated clade 1 and 2
1 [2]. The
majority of the recently isolated viruses in North
America and the UK belong to the Florida
sublineage clades 1 and 2, respectively [2].
Vaccines for EIV have been available since
the 1960s, but EIV continues to cause episodic
outbreaks of disease worldwide in both vacci-
nated and unvaccinated horses. Historically
vaccines against EIV have consisted of inacti-
vated whole virus preparations mixed with dif-
ferent adjuvants [15, 30]. Vaccine strains used
have also varied worldwide. Protection induced
by this type of vaccine is primarily mediated by
antibodies against the haemagglutinin surface
glycoprotein (HA). Protection correlates with
serum antibody levels as measured by single
radial haemolysis (SRH) [20, 21, 34]. Previous
work using a Welsh Mountain pony challenge
model showed that protection from experimen-
tal infection with EIV correlated with the
antigenic relatedness of the vaccine to the chal-
lenge virus strain [6, 37].
Natural infection with EIV confers a long-
termimmunitytore-infectionwithahomologous
strainevenintheabsenceofantibodiesatthetime
of re-infection [11]. In order to mimic more clo-
sely the protective immunity induced by EIV, a
new generation of vaccines has been designed
to stimulate both antibody and cell-mediated
immunity [26]. In addition to improvements in
vaccine technology, efforts have been made by
anumberoflaboratoriestomonitortheantigenic-
ity of circulating EIV strains in order to provide
data for appropriate vaccine strain selection.
Currently there is recommendation for a Florida
sublineage isolate (A/eq/South Africa/4/03-like)
or equivalent
1. Modern vaccine technologies
are now being employed for EIV vaccination
including the use of Immuno-stimulating com-
plexes (ISCOM) and matrices [4, 12, 13, 23,
26, 29] and recombinant poxvirus vectors [10,
19]. At the time of this study, the ProteqFluTM
vaccine (Merial Animal Health Ltd, Harlow,
UK) contained two recombinant canarypox
viruses expressing the HA of A/eq/Kentucky/94
(Americanlineage,H3N8)andA/eq/Newmarket/
2/93 (Eurasian lineage, H3N8). This vaccine
was shown to signiﬁcantly reduce clinical signs
and to prevent virus shedding in ponies chal-
lenged 2 weeks post V2 with A/eq/Newmarket/
5/03 [10, 27]. A/eq/Newmarket/5/03 is a mem-
ber of the Florida sublineage clade 2 viruses
commonly found in the UK and was responsi-
ble for the large outbreak seen in vaccinated
horses in Newmarket in 2003 [25]. The authors
note that since this study was conducted
Merial has updated its ProteqFluTM vaccine to
now include the virus strain A/eq/Ohio/03
(American lineage, H3N8), as recommended
by the OIE in 2006
2.
EquipTM F (Schering Plough Animal Health,
Hertfordshire, UK) was an ISCOM-based vac-
cine containing the strains A/eq/Newmarket/77
(H7N7), A/eq/Kentucky/98 (American lineage,
H3N8)andA/eq/Borlange/91(Eurasianlineage,
H3N8). It was shown to signiﬁcantly reduce
clinical signs and to prevent virus shedding in
ponies after experimental infection with A/eq/
South Africa/4/03 2 weeks post second vac-
cination (V2) [8, 29]. A/eq/South Africa/4/03
1 OIE, Conclusion and recommendations from the
Expert Surveillance Panel on Equine Inﬂuenza
Vaccines, 2008, pp. 42–45. http://www.oie.int/eng/
publicat/BULLETIN%20PDF/Bull%202008-2-ENG.
pdf [consulted 21 October 2008].
2 OIE, Conclusion and recommendations from the
Expert Surveillance Panel on Equine Inﬂuenza
Vaccines, 2006, pp. 35–36. http://www.oie.int/eng/
publicat/BULLETIN%20PDF/Bull%202006-2-ENG.
pdf [consulted 12 November 2007].
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naı ¨ve horses in South Africa and is representa-
tive of the Florida sublineage clade 1 viruses.
Both vaccines were able to induce EIV-speciﬁc
IFN-c synthesis by peripheral blood lympho-
cytes, suggesting the vaccines stimulated cell-
mediated immunity by directly activating Th1
cells [27, 29].
In mid-August 2007 an outbreak of EIV was
detected in a partially vaccinated horse popula-
tion in Japan [14, 36]. Later that month EIV
was detected in a naı ¨ve population in Australia
3.
EIV infection spread rapidly in both countries,
eventually infecting over 75 000 animals in
Australia [9]. Molecular characterisation of the
representative virus A/eq/Sydney/2888-8/07 has
classiﬁeditasamemberoftheFloridasublineage
clade 1 viruses, typical of viruses recently
isolatedin NorthAmerica. Of particularconcern
totheracingindustryintheUKwastheapparent
vaccine breakdown observed in Japan. The
vaccine used was a whole inactivated EIV
vaccine containing the strains A/eq/La Plata/93
(American lineage, H3N8), A/eq/Avesta/93
(Eurasianlineage,H3N8) andA/eq/Newmarket/
77 (H7N7) [36]. These strains are phylogeneti-
cally similar to the strains used in the vaccines
available in the EU at the time. This raised the
concern that vaccines available at the time may
have also been vulnerable to breakdown when
challenged with this or a related virus, as seen
in 2003 with the emergence of A/eq/Newmar-
ket/5/03 that infected both vaccinated and non-
vaccinated equids in Europe [1, 25].
Here we determine the level of protection
provided by two modern vaccines, namely
EquipTM F and ProteqFluTM, against experimen-
tal infection with a virus isolated from the
Australian EIV outbreak in 2007. To this end
Welsh Mountain ponies were challenged 2
w ee kspo stV 2t ore ﬂ e ctasi t u at i oni nw h ic ha ni -
mals would be vaccinated during an outbreak.
Virusshedding,akeyelementtocontrolinorder
to halt viral spread, was monitored using three
different methods. The long-term immunity of
poniesexperimentallyinfectedwiththephyloge-
netically-related isolate A/eq/South Africa/4/03
was also tested.
2. MATERIALS AND METHODS
2.1. Vaccine
Two vaccines commercially available in the EU
were used in the study; ProteqFlu
TM (Merial Animal
Health Ltd, batch number L212428) containing two
recombinant canarypox viruses expressing the HA
of A/eq/Newmarket/2/93 and A/eq/Kentucky/94
and an ISCOM-based vaccine, Equip
TM F (Schering
Plough Animal Health, batch number A582A2) con-
taining inactivated antigens from A/eq/Newmarket/
77, A/eq/Borla ¨nge/91 and A/eq/Kentucky/98.
2.2. Animals
Nineteen Welsh Mountain ponies aged between
1–2 years were used on the study. They were kept
in accordance with the animal care guidelines of
the Animal Health Trust Ethical Review Committee
and under a home ofﬁce project licence. Ponies were
identiﬁed by a microchip in the neck. The sera of the
15 unvaccinated animals were tested by haemagglu-
tination inhibition (HI) assay [5] and were seronega-
tive for EIVat the start of the study. The four ponies
previously infected with A/eq/South Africa/4/03
(18 months prior to the current study) were seroneg-
ative prior to the initial challenge. During the vacci-
nation phase, ponies were kept together at grass.
During the challenge phase, ponies were housed
in the Allen Centre for Vaccine Studies (ACVS),
an ACDP (Advisory Committee on Dangerous
Pathogens) category 3 containment facility.
2.3. Challenge virus
Equine inﬂuenza virus strain A/eq/Sydney/
2888-8/07 (Passage 4 in eggs) was passaged once
in ovo to provide the challenge stock (Passage 5).
EIV suspensions were titrated in embryonated hen’s
eggs using the method of Reed and Muench and
expressed in 50% egg infectious doses per mL
(EID50/mL).
2.4. Vaccination protocol
The 15 naı ¨ve ponies were randomly assigned to
three groups of 5. Control ponies (Group 1) were
3 Callinan I., Equine Inﬂuenza: The August 2007
outbreak in Australia, Commonwealth of Australia,
2008, www.equineinﬂuenzainquiry.gov.au.
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doses of ProteqFlu
TM and ﬁve ponies (Group 3)
received two doses of Equip
TM F, both 5 weeks apart
and by deep intramuscular injection into the neck.
Group 4 contained 4 ponies experimentally infected
with A/eq/South Africa/4/03 18 months prior to the
current study. These ponies were not vaccinated.
All ponies were clinically examined daily from the
day before and up to 3 days after each vaccination
step. Rectal temperatures between 37.0  Ca n d
38.8  C were considered within the normal range.
2.5. Challenge protocol
Ponies were challenged on day 49, 2 weeks
post V2. Each group of ponies was exposed to an
aerosol of approximately 20 mL of allantoic ﬂuid
diluted in PBS containing 10
7.7 EID50 of A/eq/
Sydney/2888-8/07 virus (after back titration in eggs)
using a model ULTRA 2000 nebuliser (DeVilbiss,
Somerset, PA, USA). Air handling within the
ACDP category 3 containment facility was reduced
for the duration of the challenge protocol (60 min).
Each pony was examined clinically from 1 day
before challenge through to 14 days post-challenge,
then released to pasture following full recovery.
Clinical signs of disease (nasal discharge, cough, in-
appetance, lethargy and dyspnoea) were recorded
for each pony on each day resulting in an overall
clinical score per day as described previously [10].
Ponies exhibiting signs consistent with the develop-
ment of a secondary bacterial infection were treated
with trimethoprim potentiated sulphonamide antibi-
otic (Trimediazine; Fort Dodge Animal Health,
Southampton, UK) according to the data sheet rec-
ommended dose.
2.6. Serology
Jugular venous blood samples were collected
f r o me a c hp o n yo nd a y s 7, 0 (immediately before
V1), 14, 28, 35 (immediately before V2), 42, 49
(immediately before challenge), 56, 63 and 77.
Serum was tested for the presence of antibody to
EIV challenge strains (A/eq/South Africa/4/03 and
A/eq/Sydney/2888-8/07) and to representatives of
vaccine strains (A/eq/Newmarket/1/93 and A/eq/
Newmarket/2/93) using the SRH assay [35]. SRH
antibody levels were expressed as the area of the
zone of haemolysis in mm
2 and were measured in
duplicate. Seroconversion was deﬁned as an increase
in the haemolysis zone of 25 mm
2 or 50% between
pre- and post-infection sera.
2.7. Virus detection
Nasopharyngeal swabs were taken from each
pony on the day of V1, the day before challenge,
the day after challenge and for each subsequent day
until 2 weeks post-challenge [24]. Swabs were placed
in sterile tubes containing 5 mL virus transport med-
ium (VTM) consisting of PBS, 200 U/mL streptomy-
cin, 150 U penicillin, 5 mg/mL fungizone (Gibco)
and 600 mg/mL tryptone phosphate broth. All subse-
quent work was carried out within a class 2 microbi-
ological safety cabinet (SCR-327, Labcaire Systems
Ltd, Avon, UK) using sterile instruments for each
swab. Swabs were wrung out and the resultant extract
was stored at  70  C. Suspensions were diluted
10-fold from neat to 10
 4 and 100 lLf r o me a c h
dilution was inoculated into the allantoic cavities of
10 day old embryonated hens’ eggs (two eggs per
dilution). Eggs were incubated at 34  Ca n dh a r -
vested 3 days post-infection. Virus was detected by
HA assay using 1% chicken erythrocytes in PBS
and viral titre was expressed as EID50/mL swab
extract. Extracts were also tested for the presence
of virus using the NP-ELISA as previously described
[3]. The cut-off point for positive samples for the NP-
ELISA was set at twofold background. Quantitative
RT-PCR reactions were set up within HEPA ﬁltered
laminar ﬂow hoods (PCR6, Labcaire Systems Ltd)
and was carried out using a Techne Quantica
 .V i r a l
RNA was isolated from 140 lL nasopharyngeal
swab extract using the QIAampViral RNA mini kit
(Qiagen) according to the manufacturer’s instructions
a n de l u t e di n5 0lL. RNA standards were included
alongside the nasopharyngeal swab extracts. Primers
and a ﬂuorescent probe incorporating 8 locked
nucleic acids (Proligo) targeting segment 5 (NP) were
designed using the Beacon Designer 6.0 program
(Biosoft) and were as follows: NP forward primer
50-TTCTGGAGAGGTGAAAATGG-30, NP reverse
primer 50-CATAAACACAGGCAGGTAGG-30,N P
probe 50-(6FAM)-ACCAGAATTGCTTATGAAAG
AATG-(BHQ1)-30. The quantitative RT-PCR reac-
tion was conducted using a Quantace 1 step kit
(Cat no. QT 205-02) consisting of 1· SensiMix
one step buffer, 250 nM forward and reverse primer,
165 nM probe, 3.8 mM MgCl2, 4U RNase Inhibi-
tor, and 2 lL of extracted RNA solution per reac-
tion. The program used consisted of an RT step of
42  C for 30 min, a hot start activation step of
95  C for 10 min followed by 45 cycles of 95  C
for 15 s, 60  Cf o r1m i na n d7 2 C for 30 s. Each
sample was tested in duplicate wells. Data was ana-
lysed using the Techne Quansoft program version
1.1.21. A cut-off value of 100 copies from 5.6 lL
Vet. Res. (2010) 41:19 N.A. Bryant et al.
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2.8. Statistical analysis
This study tested the null hypotheses that the
severity of clinical signs and amount of viral shed-
ding were not different between groups of vaccinated
and non-vaccinated ponies. Statistically signiﬁcant
differences in the different parameters measured
(serological responses, clinical scores, and total and
peak levels of virus shedding) between groups of
vaccinated and non-vaccinated animals were evalu-
ated using either the parametric one-way analysis of
variance (ANOVA) or non-parametric Kruskal Wallis
test, depending on whether the data were normally
distributed and had equal variances. Stata 9 software
(StataCorp, College Station, Texas, USA) was used
for analyses and the level of statistical signiﬁcance
was set at p   0.05.
3. RESULTS
3.1. Antibody responses to vaccination
or previous infection
Antibody levels were tested by SRH assay
against 4 different antigens: 2 representatives
of vaccine strains (i.e. A/eq/Newmarket/1/93
and A/eq/Newmarket/2/93) and 2 challenge
strains (A/eq/South Africa/4/03 and A/eq/
Sydney/07). None of the 15 naı ¨ve ponies had
detectable EIV-speciﬁc HI antibodies at the
beginning of the study (data not shown). The
mean serum SRH antibody responses following
V1, V2 and challenge infection with A/eq/
Sydney/2888-8/07 for each of the four groups
are reported in Table I. All 5 control
ponies (Group I) had undetectable EIV-speciﬁc
SRH antibody levels throughout the vaccina-
tion phase. They all seroconverted to EIV
when measured by SRH assay against
A/eq/South Africa/4/03,A/eq/Sydney/2888-8/07,
A/eq/Newmarket/2/93 and A/eq/Newmarket/1/
93 after experimental infection (Tab. I). After
2 weeks post V1, the vaccinated ponies in
Group 2 (ProteqFluTM) had mean antibody lev-
els of between 75 and 142 mm
2 and ponies in
Group 3 (EquipTM F) had mean zone areas of
between 17 and 145 mm
2 when using A/eq/
South Africa/4/03 as the antigen. At 2 weeks
post V2, on the day of challenge, antibody
levels were measured against the vaccine com-
ponents or related viruses antigenically as close
as possible to the vaccine strains [2]. Antibody
levels were between 118 mm
2 and 167 mm
2
(mean value of 146 mm
2)f o rG r o u p 2
(ProteqFluTM) and between 93 mm
2 and
209 mm
2 (meanvalue of 133mm
2)f o rG r o u p3
(EquipTM F) when tested against A/eq/Sydney/
2888-8/07, the challenge strain. SRH antibody
levels of between 116 and 186 mm
2 (mean
value of 146.6 mm
2) in Group 2 (ProteqFluTM)
and between 97 and 209 mm
2 (mean value of
154 mm
2) zone areas in Group 3 (EquipTM F)
using A/eq/South Africa/4/03 as the antigen that
is genetically closely related to A/eq/Sydney/
2888-8/07. Similar antibody levels of between
132 mm
2 and 177 mm
2 (mean value of
150 mm
2) for Group 2 (ProteqFluTM)a n d
between 81 mm
2 and 189 mm
2 (mean value
of 128 mm
2) for Group 3 (EquipTM F) were
obtained when using A/eq/Newmarket/1/93 as
the antigen in the SRH assay that was closely
related to a component of ProteqFluTM and
closely related to A/eq/Borlange/91 in Equip
F. At 2 weeks post-challenge, the 5 ponies in
Group 2 seroconverted after challenge infection
when tested by SRH against A/eq/Sydney/
2888-8/07 and A/eq/Newmarket/2/93 but only
3 seroconverted when tested against A/eq/
South Africa/4/03 and A/eq/Newmarket/1/93.
Against A/eq/South Africa/4/03 these three
ponies had the lowest mean SRH antibody lev-
els before challenge of between 116 and
170 mm
2, while the resistant ponies had levels
of 174 and 186 mm
2.A t2w e e k sp o s t -
challenge, 4 of the 5 ponies in Group 3 serocon-
verted when comparing pre- and post-challenge
sera against A/eq/South Africa/4/03 and A/eq/
Sydney/2888-8/07 antigens in the SRH assay.
These four ponies had the lowest mean pre-
challenge SRH antibody levels of between 97
and 167 mm
2 while the resistant pony (#3689)
had an SRH antibody level of 209 mm
2 against
both antigens (Tab. I). When tested against
A/eq/South Africa/4/03 and A/eq/Newmarket/
1/93, 4 and 2 of the ponies seroconverted respec-
tively. SRH assays on sera from the previously
infected ponies detected the presence of antibod-
ies with a mean clearance zone pre-challenge
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2 for pony #5146, the levels of which
were steady over the entire protocol (Tab. I).
Antibodies were also detected by SRH for
ponies #4818 and #4900 even though they were
not vaccinated, albeit at relatively low levels of
between 0 and 41 mm
2. Three of the four previ-
ously infected ponies seroconver-ted after chal-
lenge infection when tested against A/eq/South
Africa/4/03 (the initial challenge strain). All four
ponies seroconverted when tested against others
antigens,buttomuchlowerlevelsthantheunvac-
cinated control ponies. The exception was Pony
#5875, which had no detectable antibody by
SRH throughout the vaccination procedure, sero-
converted to the highest level within the group to
a mean antibody level of 142 mm
2 against A/eq/
South Africa/4/03. Ponies #4818 and #4900 sero-
converted but did not reach the same mean SRH
antibody levels as pony #5875, both reaching a
level < 90 mm
2.
Mean SRH antibody levels obtained using
the two Florida clade one viruses A/eq/South
Africa/4/03 and A/eq/Sydney/2888-8/07 were
not signiﬁcantly different from each other
(p = 0.23; data not shown).
3.2. Clinical responses to infection
Four out of ﬁve control (Group 1) ponies
developed pyrexia by day 2 post-infection with
a mean temperature of 39.7 ± 1.1  C( Fig. 1).
The pyrexia was biphasic in 3 out of 4 positive
ponies as it dropped below the threshold for
p y r e x i ao nd a y3a n d4w i t ham e a nt e m p e r a t u r e
of 38.2 ± 0.25  C and 38.1 ± 0.2  Cf o rt h e
group, respectively. On day 5 post-infection, a
mean temperature of 39.7 ± 0.8  Cw a s
recordedfortwoofthepreviouslypyreticponies,
lasting only one day. One control pony (#3791)
became pyretic again on day 9 post-infection.
Such elevation of body temperature late in the
challenge phase was most likely associated with
a secondary bacterial infection, which resolved
quickly after treatment with antibiotics.
Group 2 ponies vaccinated with ProteqFluTM
did not develop pyrexia post-infection with a
meantemperatureof38.0 ±0.2  C for the group
forthedurationofthemonitoringperiod(Fig.1).
One pony in Group 3 vaccinated with EquipTM F
was pyretic on days 3, 4 and 5 with a mean tem-
perature of 39.3 ± 0.1  C before returning to
baseline levels. Another pony in Group 3 was
pyretic at day 6 post-infection for one day only
withatemperatureof39.6  C.Noneoftheother
poniesinGroup 3becamepyreticoverthemon-
itoring period. One of the previously infected
ponies in Group 4 became pyretic on day 3
post-infection which persisted for 2 days with a
mean temperature of 39.9 ± 0.5  C. None of
the other previously infected ponies developed
pyrexia over the monitoring period.
A clinical score was calculated per pony as
referenced in Materials and Methods and is
shown in Figure 2. The post-challenge clinical
score was signiﬁcantly reduced (p = 0.026) in
vaccinated and previously infected ponies
(Groups2,3and4)whencomparedtotheunvac-
cinatedponies(Group 1).Signiﬁcantdifferences
were also observed in levels of coughing
(p = 0.0135) and mucopurulent nasal discharge
(p = 0.0139) when compared to control ponies.
3.3. Virus shedding
All control ponies (Group 1) shed live virus
for a minimum of three to a maximum of 7 days
post-challenge with a peak virus titre in eggs of
4.0 log10EID50/mL recovered from one pony on
d a y3( Figs. 3A and 3B). NP-ELISA positive
data generally correlated well with isolation of
live virus. Virus shedding appeared to be bipha-
sic with lower NP-ELISA values collected on
day 5 when compared to days 3, 4 and 6. Quan-
titative RT-PCR analysis mirrored the biphasic
data observed in the NP-ELISA assay with
peak copy numbers between 2.5 · 10
7/mL
and 4 · 10
8/mL on day 3 and between
2.9 · 10
5/mL and 2.1 · 10
8/mL on day 6
post-infection. Viral RNAwas detected on days
1 and 2, one day earlier than in the egg titration
and 2 days earlier than the NP-ELISA for
4 of the 5 ponies. Pony #1992 was virus posi-
tive in eggs on day 1 which corresponded to
approximately 900 copies/mL detected by
quantitative RT-PCR. Furthermore, at days 8
to 10 the egg isolation and NP-ELISA assays
were negative while viral RNA copies were
still detected, albeit at lower levels than for
earlier days post-infection. Up to approxi-
mately 2 · 10
4 copies/mL were detected for
Protection against 2007 outbreak EIV isolate Vet. Res. (2010) 41:19
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minimum of 2.5 · 10
3 copies/mL for pony
#3241 on day 10. Three of the four ponies pre-
viously infected with A/eq/South Africa/4/03
shed virus as determined by egg titration
(Figs.3Cand3D),for1to3dayswithapeaktitre
of 2.5 log10EID50/mL. The data from the NP-
ELISAsuggeststhattherewerelowlevelsofpro-
tein present when compared to the other groups
within the study, although relatively high titres
were measured in eggs in the case of pony num-
bers #5146 and #5875. On day 6 the NP-ELISA
was positive for one pony but no virus was
detected in eggs suggesting viral components
werepresentbutinaninactiveform.Thequanti-
tativeRT-PCRdatashowedvirussheddingforall
four poniesforup toapproximately 7days post-
infection with peaks obtained for ponies #5146
and #5875 on day 3 and 6 respectively. Interest-
ingly, pony #4900 that tested negative for virus
shedding by NP-ELISA and eggs on day 2, 3
and 4 was positive by quantitative RT-PCR with
a peak titre of 5.7 · 10
4 copies/mL.
Four of the ﬁve ponies in Group 2 (Proteq-
FluTM)s h e dl i v ev i r u sf o r1t o2d a y sp o s t - i n f e c -
tion with two of the ponies secreting a peak titre
of 1.5 log10EID50/mL on day 2 as determined
by egg titration (Figs. 3G and 3H). EIV was
detected one day earlier in eggs for two ponies
when compared to the NP-ELISA assay. Quan-
titative RT-PCR detected viral RNA from the
ﬁve poniesforatleast7dayspost-infectionfrom
days1or2todays8or9dependingonthepony.
The biphasic nature of virus shedding was
evident for ponies #2217, #3409 and #5728.
Absolute copy number values were reduced in
ponies#3409,#3712and#5728whencompared
to controls. Furthermore, the NP-ELISA and
quantitative RT-PCR detected virus in swab
material that was unable to replicate in eggs on
days 2 to 8. Two of the ﬁve ponies in Group 3
(EquipTM F) shed live virus over the monitoring
period for 2 to 3 days, with a peak titre of 3.0
log10EID50/mL on day 4 post-infection for pony
number #3013. The NP-ELISA detected protein
at the same time points at which virus replicated
in the embryonated eggs, namely days 2 and 3
but not on day 4 or day 6. The quantitative
RT-PCR assay detected RNA copies for a
minimum of 7 days post-infection for the ﬁve
ponies (Figs. 3E and 3F). Ponies #3013 and
#3170 had peak copy numbers of 2.4 · 10
8
and 3.7 · 10
7 copies/mL on day 2 respectively,
whichdroppedrapidlyuntilasecondlowerpeak
was recorded on day 6 post-infection with tires
of 2.2 · 10
5 and 3.4 · 10
5 copies/mL. Further-
more, pony #6202 which tested negative by
egg titration and NP-ELISA throughout the
challenge period had slowly increasing copy
numbers from day 3 post-infection peaking at
3 · 10
7 copies/mL on day 6.
There were statistically signiﬁcant differ-
ences between the total amount of virus and
the peak virus shed between the control group
(Group 1) and the vaccinated groups (p =
0.007) or the previously infected group (p =
0.005) as measured by egg titration.
4. DISCUSSION
It is most likely that the 2007 Australian out-
break of EI was initiated by a subclinically
infected imported horse that had responded
poorly to vaccination
3. The A/eq/Sydney/
2888-8/07 strain classiﬁed as a member of the
Florida sublineage clade 1 was very similar to
viruses isolated from the 2007 EIV outbreak
in Japan where numerous cases of vaccine
breakdown were reported
3 [14, 36]. Further-
more, the Japanese vaccines used in 2007
Figure 2. Total clinical scores for the four groups
of ponies for 14 days post-challenge with A/eq/
Sydney/2888-8/07 as identiﬁed by the legend. Data
includes rectal temperatures, nasal discharge,
cough, inappetance, lethargy and dyspnoea.
Protection against 2007 outbreak EIV isolate Vet. Res. (2010) 41:19
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(page number not for citation purpose) Page 11 of 15contained similar EIV strains to vaccines com-
mercialised in the UK in 2003. Analysis of
the EIV outbreak in Newmarket in 2003 dem-
onstrated that protection induced by those vac-
cines was sub-optimal [1]. These data raised
concerns about the efﬁcacy of vaccines avail-
able in Europe against these more recent strains
in the absence of any updated vaccines on the
market [1]. This study was supported by the
Horserace Betting Levy Board and designed
to test the efﬁcacy of two EIV vaccines com-
mercially available in the UK at the time of
the Japanese and Australian outbreaks, against
infection with A/eq/Sydney/2888-8/07 strain.
It offered a better understanding of the options
available to the equine industry in order to con-
trol or limit the spread of a similar EIV strain if
it came to circulate in Europe, in the absence of
updated EI vaccines.
In a Welsh Mountain pony model both
EquipTM F (Schering Plough) and ProteqFluTM
(Merial) were partially protective when chal-
lenged with A/eq/Sydney/2888-8/07, resulting
in signiﬁcantly reduced clinical signs of disease
and virus shedding as measured in eggs and by
quantitative RT-PCR when compared to unvac-
cinated ponies. This protection was achieved
with 2 doses of vaccine administered 5 weeks
apart as seen in previous efﬁcacy studies with
relatedEIVstrains[10,27,29].However,neither
vaccine completely prevented virus shedding,
despite the challenge taking place under opti-
misedconditionswithhighantibodylevels.This
sub-optimal performance could be associated
with the differences between vaccine and
challenge strains. The vaccines used in this
study contained A/eq/Kentucky/1/93 or A/eq/
Kentucky/98HA,bothAmericanlineageviruses
with 10and13amino acidsubstitutions inHA1,
respectively when compared to A/eq/South
Africa/4/03 (the recommended vaccine strain)
and 12 and 15 amino acid substitutions when
compared with A/eq/Sydney/2888-8/07. Anti-
body levels as measured by SRH ranged from
about 96 to 209 mm
2 for EquipTM F and about
115 to 186 mm
2 for ProteqFluTM at 2 weeks post
V2 using A/eq/South Africa/4/03 as the antigen.
The SRH values raised against A/eq/Sydney/
2888-8/07 in the assay ranged from 93 to
209 mm
2 for EquipTM F and 117 to 168 mm
2
for ProteqFluTM. These SRH values are broadly
similar for both antigens reﬂecting their close
antigenic relationship (only 2 amino acids sub-
stitutions in HA1) and them both being mem-
bers of the Florida sublineage clade 1
3 [2].
Interestingly, the SRH values obtained when
using A/eq/Newmarket/1/93 antigen on sera
from V2 + 2 weeks (pre-challenge) were also
broadly similar to those seen with A/eq/Syd-
ney/2888-8/07 and A/eq/South Africa/4/03 sug-
gesting the antibody response was crossreactive
in this assay. Pre-challenge SRH antibody lev-
els against A/eq/Newmarket/2/93 for both vac-
cines were lower than those seen with those
raised against the Florida sublineage viruses
however after challenge all SRH antibody lev-
els against A/eq/Newmarket/2/93 showed clear
seroconversions to levels similar to the other
antigens. The critical value for clinical protec-
tion was previously determined as 100 mm
2
against the challenge virus, and levels of
150 mm
2 and greater where shown to protect
from virus shedding when using conventional
inactivated vaccines [22]. These values were
reduced to 90 mm
2 and > 120 mm
2 respec-
tively, when using ISCOM vaccines with a
lower heterologous challenge dose of 10
6
EID50/mL of A/eq/Newmarket/79 [23]. Based
on these data, it would appear unlikely that
one dose alone of either vaccine would induce
antibody levels high enough in naı ¨ve ponies
to protect against virus infection post V1 alone
in a heterologous challenge, the most likely sce-
nario in an outbreak situation. This suggests it
may be necessary for horse populations to
undergo a complete vaccination schedule to
ensure efﬁcacy in a naı ¨ve population. In this
study ponies with mean SRH antibody levels
of as high as 167 and 169 mm
2 on the day of
challenge after prime/boost immunisation with
either vaccine did seroconvert after experimen-
tal infection with A/eq/Sydney/2888-8/07. This
result indicated that neither vaccine provided
sterile immunity against the Australian outbreak
isolate, despite being tested under optimal con-
ditions that are likely to provide a high level of
protection.
In the ﬁeld it is unlikely that all vaccinated
animals would respond to the samelevel as seen
here, and horses are likely to be at different
Vet. Res. (2010) 41:19 N.A. Bryant et al.
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they encounter EIV. Antigenic drift in equine
H3N8 viruses further reduces the efﬁcacy of
vaccines and can lead to these viruses not being
recognised by pre-existing antibodies generated
by infection or vaccination with an antigenically
distant strain. Previous studies with non-adju-
vantedinactivatedvirus vaccines havebeenable
to identify differences between the level of pro-
tection provided against homologous and heter-
ologous challenge [6, 7, 37]. For this reason the
OIE has recommended for several years that
EIV vaccines be updated to include a Eurasian
lineage strain (e.g. A/eq/Newmarket/2/93) and
a Florida sublineage clade 1 virus (e.g. A/eq/
South Africa/4/03)
1. At the time of this experi-
ment, no vaccine was available in the UK that
met these requirements. The authors fully sup-
port the OIE recommendation and note that vac-
cines containing these updated strains are now
available. As of 2009, the OIE has dropped
the recommendation for a Eurasian lineage
strain to be included in EIV vaccines as they
are no longer circulating in the ﬁeld
4.I nt h e
Newmarket EIV outbreak in 2003 there were
numerous reports of vaccine breakdown
although the vaccines themselves were inducing
high antibody levels that would normally con-
s id er e dt obepr ot e ct i ve[ 25].Vaccinesemployed
in Newmarket in 2003contained A/eq/Newmar-
ket/1/93 with aluminium hydroxide adjuvant.
Later work has suggested that protective immu-
nity conveyed by these vaccines was sub-opti-
mal compared to other vaccines preparations
[1]b u tw h e t h e rt h i sw a st h ec a s ei nJ a p a no r
not has not been determined.
The vaccines tested in this report have been
shown to generate an EIV-speciﬁc IFNc
response, which is a marker of cell-mediated
immunity in the horse [27–29]. In man, it is
thought that cellular immune mechanisms play
an important role in clearance of virus from
the respiratory tract [18]. Infection with EIV
has been shown to induce long-term immunity
independent of circulating antibodies against
HA [11]. Of the previously infected ponies
studied in this report, 3 of the 4 had detectable
SRH antibody levels 18 months post-infection
with only one above 75 mm
2. Antibody levels
after natural EI infection usually wane rapidly.
The antibody response was monitored regularly
in this group of ponies after the initial experi-
mental infection with A/eq/South Africa/4/03.
SRH antibodies were still detectable 12 months
after the initial EIV infection (between 22 to
75 mm
2; data not shown), which was consistent
with the data presented in this report. Kinetics
of the antibody response shown a slow decrease
instead challenge infection, without evidence of
anamnestic response (data not shown). No evi-
dence of ﬁeld EI infection (clinical signs or
serology) were recorded on the premise where
these four ponies and other EIV naı ¨ve ponies
were kept during the 18 months separating the
2 experimental infection with EIV (A/eq/South
Africa/4/03andA/eq/Sydney/2888-8/07,respec-
tively). This pony did not seroconvert after
challenge infection but it did shed virus on days
3 and 4, suggesting that it was productively
infected with virus. During the vaccination
phase, two of the other previously infected
ponies (Group 4) developed low but detectable
levels of antibody, speciﬁc for EIV despite not
being vaccinated.
After challenge infection with A/eq/Sydney/
2888-8/07, the level of SRH antibody was sig-
niﬁcantly lower than in other groups (p < 0.01),
with only 3 out of 4 ponies seroconverting. All
previously infected ponies in Group 4 showed
signiﬁcantly reduced clinical signs of disease
and virus shedding when compared with con-
trol ponies. This result conﬁrms the previous
observations that horses that have previously
been in contact with EIV develop an EIV-
speciﬁc memory response that is rapidly stimu-
lated and able to provide signiﬁcant protection,
despite absent or low levels of antibody at the
time of infection. Both B and T cell memory
responses are expected to be quickly stimulated
by re-infection with EIV, their respective impor-
tance and role in protection is still unclear.
Three different methods were used for quan-
tifying the amount of virus shed and collected
by nasopharyngeal swabbing. To date most
4 Expert surveillance panel on equine inﬂuenza
vaccine composition – Conclusions and recom-
mandations, 2009, pp. 42–43. http://www.oie.int/
eng/publicat/BULLETIN%20PDF/Bull%202009-2-
ENG.pdf.
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been conducted using egg titration as the
method of choice, with the obvious advantage
of detecting only infectious virus [8, 10, 19,
29]. However, this study has shown that quan-
titative RT-PCR was more sensitive than both
virus isolation in eggs and NP-ELISA, detect-
ing viral RNA earlier and for longer than the
other methods even in ponies showing no clin-
ical signs of EIV infection. The quantitative
RT-PCR protocol was able to detect less than
10 RNA copies when using in vitro transcribed
RNA template. A limitation of the egg titration
protocol used was that it relies on just one egg
passage at 4 different virus dilutions from neat
to 10
 4 and detection by HA assay that itself is
notverysensitive.Virus isolationfrom nasopha-
ryngeal swabs taken from horses in the ﬁeld can
take up to 5 egg passages before an HA positive
eggisobtained[2].Thismayaccountforsomeof
the negative results obtained in eggs when com-
pared to NP-ELISA or quantitative RT-PCR.
Another alternative explanation for this result
maybethatthevirusparticlespresentinthenasal
secretionsmayberenderednon-infectionsbythe
bindingofsecreted antibody, particularly in vac-
cinated ponies with high antibody levels.
In conclusion the results obtained in this
study suggested that both vaccines should pro-
vide a reasonable level of clinical protection
for UK horses if a strain of EIV similar to that
occurring in Australia or Japan were to become
established in this country. Since they reduced
thelevel and duration ofvirus shedding,thecur-
rent vaccines should also help reduce the spread
of the disease, particularly if used in the face of
an outbreak where high herd immunity can be
induced at a local level in the short term before
updated vaccines became available. We fully
endorse the recommendations of the OIE Expert
Surveillance Panel who continue to recommend
thatcurrentvaccinesbeupdatedtoamorerecent
virus (A/eq/Ohio/03 or A/eq/South Africa/
4/03)
4. We strongly believe that inclusion of
such a strain in vaccines would further improve
prevention and control of EIVoutbreaks.
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